Lv1
50 积分 2021-06-28 加入
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
1天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
16天前
已完结
Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era
1个月前
已完结
“Blasts” in myeloid neoplasms – how do we define blasts and how do we incorporate them into diagnostic schema moving forward?
1个月前
已完结
Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma
2个月前
已完结
Nuclear Magnetic Resonance–Based Metabolomics and Risk of CKD
3个月前
已完结
Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma
3个月前
已完结
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)
4个月前
已完结
Practical recommendations for using ctDNA in clinical decision making
4个月前
已完结
A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas
5个月前
已完结
皖公网安备34019202002308
